# US 2026/0218190 A1 · RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218190 A1
- Document ID: US20260218190A1
- Status: Published application
- Kind: A1
- Application number: 19/419,483
- Filed: 2025-12-15
- Published: 2026-07-30
- Earliest claimed: 2023-08-30
- Assignees: Arrowhead Pharmaceuticals, Inc.
- Applicants: Arrowhead Pharmaceuticals, Inc.
- Inventors: Michelle Ngai; Feng Liu; Puhui Li; Xiaokai Li; Zhi-Ming Ding; Tao Pei; Daniel Braas; So Wong; James C. Hamilton; Grigoriy Shekhtman
- Web page: https://patentgrep.com/patent/US20260218190A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/351: Conjugate
- C12N 2310/3521: Methyl
- C12N 2310/3533: Halogen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

## Claims

### Claim 1

An RNAi agent for inhibiting expression of an Inhibin Subunit Beta E (INHBE) gene, comprising:
i. an antisense strand comprising at least 17 contiguous nucleotides differing by 0 or 1 nucleotides from any one of the sequences of Table 2, Table 3, or Table 5C; and
ii. a sense strand comprising a nucleotide sequence that is at least partially complementary to the antisense strand.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The RNAi agent of claim 1, wherein at least one nucleotide of the RNAi agent is a modified nucleotide or includes a modified internucleoside linkage, wherein the at least one modified nucleotide is selected from the group consisting of: 2′-O-methyl nucleotide, 2′-fluoro nucleotide, 2′-deoxy nucleotide, 2′,3′-seco nucleotide mimic, locked nucleotide, 2′-F-arabino nucleotide, 2′-methoxyethyl nucleotide, abasic nucleotide, ribitol, inverted nucleotide, inverted 2′-O-methyl nucleotide, inverted 2′-deoxy nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholine nucleotide, vinyl phosphonate containing nucleotide, cyclopropyl phosphonate containing nucleotide, and 3′-O-methyl nucleotide.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand consists of, consists essentially of, or comprises the nucleotide sequence of any one of the modified antisense strand sequences of Table 3 or Table 5C.

### Claim 9 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand consists of, consists essentially of, or comprises the nucleotide sequence of any of the modified sense strand sequences of Table 4 or Table 5C.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent is linked to a targeting ligand.

### Claim at position 9

12-13. (canceled)

### Claim 14 (depends on 1)

The RNAi agent of claim 1, wherein the targeting ligand comprises the structure of
wherein indicates the point of connection to the RNAi agent.

### Claim 15

(canceled)

### Claim 16 (depends on 11)

The RNAi agent of claim 11, wherein the targeting ligand is linked to the 5′ terminal end of the sense strand.

### Claim 17 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is between 15 and 30 nucleotides in length, and the antisense strand is between 18 and 30 nucleotides in length.

### Claim at position 14

18-21. (canceled)

### Claim 22 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises one or two terminal caps.

### Claim 23 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises one or two inverted abasic residues.

### Claim 24 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent comprises a sense strand and an antisense strand that form a duplex sequence of any of the duplexes set forth in Table 5A, 5B, or 5C.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The RNAi agent of claim 1, comprising an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5′→3′):
(SEQ ID NO: 621)
UAUUAAGAAAGUAUAAGCCAG;
or
(SEQ ID NO: 748)
TGACAAGAAAGUGCCCAUUUG.

### Claim 27 (depends on 26)

The RNAi agent of claim 26, wherein the sense strand consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5′→3′):
(SEQ ID NO: 684)
CUGGCUUAUACUUUCUUAAUA;
or
(SEQ ID NO: 699)
CAAAUGGGCACUUUCUUGUCA.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The RNAi agent of claim 1, comprising an antisense strand that comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5′→3′):
(SEQ ID NO: 391)
usAfsuuAfagaaagUfaUfaAfgccassg;
or
(SEQ ID NO: 427)
dTssGfsacaaGfaaagUfgCfcCfauuussg;
wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, and u represents 2′-O-methyl uridine; Af, represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine; dT represents 2′-deoxythymidine; s represents a phosphorothioate linkage, and ss represents a phosphorodithioate linkage; and wherein all or substantially all of the nucleotides on the sense strand are modified nucleotides.

### Claim 30 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5′→3′):
(SEQ ID NO: 515)
cuggcuuaUfaCfUfuucuuaaua;
or
(SEQ ID NO: 530)
caaaugggCfAfCfuuucuuguca;
wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, and u represents 2′-O-methyl uridine; Af, represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine; s represents a phosphorothioate linkage and ss represents a phosphorodithioate linkage; and wherein all or substantially all of the nucleotides on the antisense strand are modified nucleotides.

### Claim at position 24

31-33. (canceled)

### Claim 34 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent is a pharmaceutically acceptable salt.

### Claim at position 26

35-36. (canceled)

### Claim 37 (depends on 1)

A composition comprising the RNAi agent of claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient.

### Claim at position 28

38-39. (canceled)

### Claim 40 (depends on 1)

A method for inhibiting expression of an Inhibin Subunit Beta E (INHBE) gene in a cell, the method comprising introducing into a cell an effective amount of an RNAi agent of claim 1.

### Claim at position 30

41-44. (canceled)

### Claim 45 (depends on 1)

A method of treating an IBE-related disease, disorder, or symptom, the method comprising administering to a human subject in need thereof a therapeutically effective amount of the RNAi agent of claim 1.

### Claim 46

(canceled)

### Claim 47 (depends on 45)

The method of claim 45, wherein the RNAi agent is administered at a dose of about 0.05 mg/kg to about 5.0 mg/kg of body weight of the human subject.

### Claim at position 34

48-62. (canceled)
